Bevacizumab, a vascular endothelial-derived growth factor (VEGF) inhibitor, apatinib, a VEGFR2 inhibitor, and sunitinib, an oral tyrosine kinase inhibitor, are all anti-angiogenic agents that have been used to treat pituitary tumors (Figure 1) [106]. Here, VEGFA is linked to pituitary tumor.